Arbutus Biopharma Corporation (ABUS): Price and Financial Metrics

Arbutus Biopharma Corporation (ABUS): $2.53

0.11 (+4.55%)

POWR Rating

Component Grades













Add ABUS to Watchlist
Sign Up

Industry: Biotech


of 450

in industry


  • ABUS scores best on the Growth dimension, with a Growth rank ahead of 80.27% of US stocks.
  • The strongest trend for ABUS is in Stability, which has been heading down over the past 169 days.
  • ABUS ranks lowest in Stability; there it ranks in the 6th percentile.

ABUS Stock Summary

  • Of note is the ratio of Arbutus Biopharma Corp's sales and general administrative expense to its total operating expenses; merely 8.76% of US stocks have a lower such ratio.
  • For ABUS, its debt to operating expenses ratio is greater than that reported by just 8.69% of US equities we're observing.
  • ABUS's price/sales ratio is 32.19; that's higher than the P/S ratio of 94.99% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Arbutus Biopharma Corp, a group of peers worth examining would be MGNX, LPTX, SYRS, SQZ, and ZYME.
  • ABUS's SEC filings can be seen here. And to visit Arbutus Biopharma Corp's official web site, go to

ABUS Valuation Summary

  • In comparison to the median Healthcare stock, ABUS's EV/EBIT ratio is 115.7% lower, now standing at -4.6.
  • Over the past 142 months, ABUS's price/earnings ratio has gone up 1.4.
  • ABUS's price/sales ratio has moved up 37.4 over the prior 142 months.

Below are key valuation metrics over time for ABUS.

Stock Date P/S P/B P/E EV/EBIT
ABUS 2021-08-31 40.7 3.4 -4.0 -4.6
ABUS 2021-08-30 40.1 3.3 -4.0 -4.5
ABUS 2021-08-27 39.5 3.3 -3.9 -4.4
ABUS 2021-08-26 38.6 3.2 -3.8 -4.3
ABUS 2021-08-25 38.7 3.2 -3.8 -4.3
ABUS 2021-08-24 38.6 3.2 -3.8 -4.3

ABUS Growth Metrics

    The 5 year net cashflow from operations growth rate now stands at -47.55%.
  • The year over year price growth rate now stands at 105.56%.
  • Its 4 year revenue growth rate is now at -67.19%.
ABUS's revenue has moved up $2,197,000 over the prior 49 months.

The table below shows ABUS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 10.168 -62.939 -86.656
2021-06-30 8.351 -59.077 -84.193
2021-03-31 7.536 -53.869 -78.622
2020-12-31 6.914 -51.441 -75.868
2020-09-30 6.146 -49.779 -83.237
2020-06-30 7.684 -61.075 -146.75

ABUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABUS has a Quality Grade of D, ranking ahead of 23.96% of graded US stocks.
  • ABUS's asset turnover comes in at 0.061 -- ranking 309th of 681 Pharmaceutical Products stocks.
  • ABBV, PLXP, and HSTO are the stocks whose asset turnover ratios are most correlated with ABUS.

The table below shows ABUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.061 1 -1.012
2021-03-31 0.059 1 -1.139
2020-12-31 0.059 1 -1.030
2020-09-30 0.056 1 -1.204
2020-06-30 0.073 1 -2.668
2020-03-31 0.053 1 -3.000

ABUS Price Target

For more insight on analysts targets of ABUS, see our ABUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.90 Average Broker Recommendation 1.7 (Moderate Buy)

ABUS Stock Price Chart Interactive Chart >

Price chart for ABUS

ABUS Price/Volume Stats

Current price $2.53 52-week high $6.50
Prev. close $2.42 52-week low $2.38
Day low $2.38 Volume 2,470,800
Day high $2.53 Avg. volume 3,067,047
50-day MA $3.57 Dividend yield N/A
200-day MA $3.42 Market Cap 342.23M

Arbutus Biopharma Corporation (ABUS) Company Bio

Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. The company is based in Burnaby, Canada.

ABUS Latest News Stream

Event/Time News Detail
Loading, please wait...

ABUS Latest Social Stream

Loading social stream, please wait...

View Full ABUS Social Stream

Latest ABUS News From Around the Web

Below are the latest news stories about Arbutus Biopharma Corp that investors may wish to consider to help them evaluate ABUS as an investment opportunity.

First Quadrant L P Buys Innoviva Inc, NOW Inc, General Electric Co, Sells , Brookfield Asset ...

Investment company First Quadrant L P (Current Portfolio) buys Innoviva Inc, NOW Inc, General Electric Co, CF Industries Holdings Inc, JPMorgan Chase, sells , Brookfield Asset Management Inc, , Roku Inc, Cardiovascular Systems Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Quadrant L P.

Yahoo | January 27, 2022

Arbutus Biopharma outlines milestones for 2022

Arbutus Biopharma (ABUS) announces its 2022 corporate objectives and provided a financial update

Seeking Alpha | January 24, 2022

Arbutus Announces 2022 Corporate Objectives and Provides Financial Update

Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for the treatment of HBV Complete IND-enabling studies for next generation oral RNA destabilizer, AB-161, for the treatment of HBVAdvance an nsp5 main protease (Mpro) inhibitor candidate into IND-enabling studies for treatment of SARS-CoV-2 Financial position significantly strengthened; cash runway into Q2

Yahoo | January 24, 2022

Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Yahoo | January 5, 2022

Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference

WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtua

Yahoo | January 4, 2022

Read More 'ABUS' Stories Here

ABUS Price Returns

1-mo -34.79%
3-mo -37.22%
6-mo -6.64%
1-year -33.07%
3-year -31.81%
5-year -0.78%
YTD -34.96%
2021 9.58%
2020 27.70%
2019 -27.42%
2018 -24.16%
2017 106.12%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7404 seconds.